1. Home
  2. ESPR vs IRWD Comparison

ESPR vs IRWD Comparison

Compare ESPR & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.39

Market Cap

898.5M

Sector

Health Care

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$4.60

Market Cap

741.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESPR
IRWD
Founded
2008
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
898.5M
741.8M
IPO Year
2013
2010

Fundamental Metrics

Financial Performance
Metric
ESPR
IRWD
Price
$3.39
$4.60
Analyst Decision
Buy
Hold
Analyst Count
6
4
Target Price
$6.67
$3.68
AVG Volume (30 Days)
5.3M
2.8M
Earning Date
03-03-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.18
Revenue
$303,802,000.00
$338,987,000.00
Revenue This Year
$27.49
N/A
Revenue Next Year
N/A
$37.22
P/E Ratio
N/A
$27.33
Revenue Growth
2.83
N/A
52 Week Low
$0.69
$0.53
52 Week High
$4.18
$5.78

Technical Indicators

Market Signals
Indicator
ESPR
IRWD
Relative Strength Index (RSI) 48.87 51.79
Support Level $3.16 $4.42
Resistance Level $3.64 $4.91
Average True Range (ATR) 0.21 0.31
MACD 0.01 -0.09
Stochastic Oscillator 61.94 16.15

Price Performance

Historical Comparison
ESPR
IRWD

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Share on Social Networks: